Table 1.
Clinical characteristics at baseline and at 12 weeks after the administration of ipragliflozin in patients with type 2 diabetes
| Baseline | 12 weeks | p values | |
|---|---|---|---|
| Age (years) | 66 ± 8 | ||
| Gender (% female) | 33 | ||
| SBP (mmHg) | 135 ± 16 | 129 ± 14 | 0.143 |
| DBP (mmHg) | 89 ± 14 | 84 ± 10 | 0.204 |
| Body weight (kg) | 59.3 ± 7.8 | 58.1 ± 7.8 | 0.011 |
| Body mass index (kg/m2) | 22.6 ± 1.8 | 22.1 ± 1.8 | 0.011 |
| Waist circumference (cm) | 86 ± 6 | 86 ± 6 | 0.973 |
| HbA1c (mmol/mol) | 55.1 ± 6.8 | 50.9 ± 4.1 | 0.011 |
| HbA1c (%) | 7.2 ± 0.6 | 6.8 ± 0.4 | 0.011 |
| Plasma glucose (mmol/l) | 7.7 (7.1–8.7) | 6.9 (6.0–7.6) | 0.050 |
| Insulin (μU/ml) | 9.1 (6.4–12.2) | 7.1 (5.2–9.8) | 0.022 |
| HOMA-IR (N = 7) | 2.28 (1.44–2.97) | 1.84 (1.41–2.02) | 0.007 |
| Triglycerides (mmol/l) | 2.49 (0.87–2.91) | 1.66 (0.75–4.04) | 0.878 |
| HDL cholesterol (mmol/l) | 1.43 ± 0.34 | 1.54 ± 0.35 | 0.042 |
| LDL cholesterol (mmol/l) | 2.92 ± 1.03 | 2.81 ± 1.08 | 0.409 |
| AST (U/l) | 21 (18–54) | 29 (18–39) | 0.878 |
| ALT (U/l) | 26 (16–55) | 25 (15–48) | 0.476 |
| γ-GTP (U/l) | 70 (32–149) | 69 (31–90) | 0.173 |
| Estimated GFR (ml/min/1.73 m2) | 79.5 ± 17.1 | 77.3 ± 15.8 | 0.488 |
| Urinary ACR (mg/g) | 14 (11–17) | 15 (8–32) | 0.510 |
| Uric acid (μmol/L) | 326 ± 68 | 281 ± 70 | 0.006 |
| Hemoglobin (g/dl) | 14.9 ± 1.6 | 15.7 ± 1.3 | 0.019 |
| CRP (mg/l) | 0.55 (0.33–3.48) | 0.40 (0.33–1.58) | 0.476 |
ACR albumin-to-creatinine ratio, ALT alanine transaminase, AST aspartate transaminase, CRP C-reactive protein, DBP diastolic blood pressure, GFR glomerular filtration ratio, GTP glutamyl transpeptidase, HDL high-density lipoprotein, HOMA-IR homeostasis model assessment as an index of insulin resistance, LDL low-density lipoprotein, SBP systolic blood pressure